Treatment Sequencing in the VISION Study of Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC

被引：0
|
作者：
Griesingerl, Frank [1 ]
Garassino, Marina [2 ,3 ]
Felip, Enriqueta [4 ]
Sakai, Hiroshi [5 ,6 ]
Le, Xiuning [7 ]
Veillon, Remi [8 ]
Smit, Egbert [9 ]
Raskin, Jo [10 ]
Thomas, Michael [11 ,12 ,13 ]
Ahn, Myung-Ju [14 ]
Lee, Matthew [15 ]
Vlassak, Soetkin [16 ,17 ]
Bruns, Rolf [18 ]
Johne, Andreas [19 ]
Palle, Paul K. [20 ]
机构：
[1] Carl von Ossietzky Univ Oldenburg, Dept Hematol & Oncol, Pius Hosp, Oldenburg, Germany
[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[3] Univ Chicago, Hematol Oncol Sect, Dept Med, Knapp Ctr Biomed Discovery, Chicago, IL USA
[4] Vali Hebron Inst Oncol VHIO, Dept Oncol, Barcelona, Spain
[5] Saitama Canc Ctr, Dept Thorac Oncol, Saitama, Japan
[6] Ageo Cent Gen Hosp, Dept Thorac Oncol, Saitama, Japan
[7] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[8] CHU Bordeaux, Serv Malad Resp, Bordeaux, France
[9] Leiden Univ, Dept Pulm Dis, Med Ctr, Leiden, Netherlands
[10] Antwerp Univ Hosp UZA, Dept Pulmonol & Thorac Oncol, Edegem, Belgium
[11] Univ Heidelberg Hosp, Thoraxklin & Natl Ctr Tumor Dis, Heidelberg, Germany
[12] Translat Lung Res Ctr Heidelberg TLRCH, Heidelberg, Germany
[13] German Ctr Lung Res DZL, Heidelberg, Germany
[14] Sungkyunkwan Univ, Hematol Oncol Sect, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea
[15] EMD Serono, Rockland, MA USA
[16] Merck NS SA, Global Med Affairs, Overijse, Belgium
[17] Merck KGaA, Darmstadt, Germany
[18] Healthcare Business Merck KGaA, Dept Biostat, Darmstadt, Germany
[19] Healthcare Business Merck KGaA, Global Clin Dev, Darmstadt, Germany
[20] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, New York, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.83
引用
收藏
页码：E37 / E38
页数：2
相关论文
共 50 条
  • [1] Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
    Scherz, A.
    Felip, E.
    Garassino, M.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E.
    Mazieres, J.
    Cortot, A.
    Raskin, J.
    Viteri, S.
    Iams, W. Thomas
    Kim, H. R.
    Yang, J. -J.
    Stroh, C.
    Otto, G.
    Bruns, R.
    Paik, P.
    SWISS MEDICAL WEEKLY, 2021, 151 : 36 - 36
  • [2] Treatment sequencing in the VISION study of tepotinib in patients with METexon 14 (METex14) skipping NSCLC
    Griesinger, F.
    Garassino, M. C.
    Felip, E.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E. F.
    Raskin, J.
    Thomas, M.
    Ahn, M-J.
    Vlassak, S.
    Bruns, R.
    Johne, A.
    Paik, P. K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S60 - S61
  • [3] Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping
    Yang, J. C-H.
    Ahn, M-J.
    Sakai, H.
    Morise, M.
    Kato, T.
    Chen, Y-M.
    Han, J-Y.
    Yang, J-J.
    Zhao, J.
    Huang, J.
    Berghoff, K.
    Bruns, R.
    Otto, G.
    Le, X.
    Paik, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S41 - S42
  • [4] Tepotinib efficacy and safety in patients with MET exon 14 (METex14) skipping NSCLC
    Garassino, Marina C.
    Le, Xiuning
    Iam, Wade T.
    Felip, Enriqueta
    Sakai, Hiroshi
    Veillon, Remi
    Smit, Egbert F.
    Mazieres, Julien
    Raskin, Jo
    Cortot, Alexis B.
    Berghoff, Karin
    Bruns, Rolf
    Otto, Gordon
    Paik, Paul K.
    CANCER RESEARCH, 2022, 82 (12)
  • [5] Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
    Viteri, S.
    Felip, E.
    Griesinger, F.
    Garassino, M. C.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E. F.
    Raskin, J.
    Thomas, M.
    Ahn, M-J.
    Vlassak, S.
    Bruns, R.
    Johne, A.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2023, 34
  • [6] Intracranial Activity of Tepotinib in Patients (pts) With MET exon 14 (METex14) Skipping NSCLC Enrolled in VISION
    Bestvina, C. M.
    Patel, J. D.
    Le, X.
    Veillon, R.
    Anderson, I.
    Demedts, I.
    Garassino, M.
    Mazieres, J.
    Morise, M.
    Smit, E.
    Eggleton, S. P.
    O'Brate, A.
    Otto, G.
    Bruns, R.
    Schumacher, K. M.
    Paik, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (02): : E14 - E15
  • [7] Efficacy and intracranial activity of tepotinib in Japanese patients with MET exon 14 skipping (METex14) NSCLC (VISION)
    Morise, Masahiro
    Sakai, Hiroshi
    Kato, Terufumi
    Matsumoto, Shingo
    Kumagai, Toru
    Sakamoto, Tomohiro
    Tokito, Takaaki
    Atagi, Shinji
    Kozuki, Toshiyuki
    Takeoka, Hiroaki
    Chikamori, Kenichi
    Shinagawa, Naofumi
    Tanaka, Hiroshi
    Hirashima, Tomonori
    Eggleton, S. Peter
    Bruns, Rolf
    Otto, Gordon
    Paik, Paul
    ANNALS OF ONCOLOGY, 2022, 33 : S475 - S475
  • [8] Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping.
    Kato, Terufumi
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Sakai, Hiroshi
    Morise, Masahiro
    Chen, Yuh-Min
    Han, Ji-Youn
    Yang, Jin-Ji
    Zhao, Jun
    Huang, Jason
    Berghoff, Karin
    Bruns, Rolf
    Vioix, Helene
    Otto, Gordon
    Le, Xiuning
    Paik, Paul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping
    Yang, J. C-H.
    Le, X.
    Cho, B. C.
    Han, J-Y.
    Morise, M.
    Chen, Y-M.
    Kang, J-H.
    Kato, T.
    Takeoka, H.
    Chikamori, K.
    Sakai, H.
    Park, K.
    Wu, Y-L.
    Schumacher, K.
    Bruns, R.
    Straub, J.
    Paik, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1390 - S1391
  • [10] Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION
    Yang, J. C-H.
    Kato, T.
    Ahn, M-J.
    Sakai, H.
    Morise, M.
    Chen, Y-M.
    Han, J-Y.
    Yang, J.
    Zhao, J.
    Huang, J. L-C.
    Berghoff, K.
    Bruns, R.
    Vioix, H.
    Otto, G. P.
    Le, X.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1565 - S1565
12345